| 2017-06-26 |
166 |
Stipulation of Dismissal |
infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”),
7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted
Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary
rights.
… 26 June 2017
1:17-cv-00823-MN
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
| 2017-06-26 |
236 |
Memorandum Opinion |
infringement of U.S.
Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the ' …393 patent"), and 8,399,514 ("the ' 514
patent") (collectively, "patents-in-suit…; 999 patent"), 7,619,001 ("the ' 001
patent"), 7,803 ,840 ("the ' 840 patent…quot;It is a bedrock principle of patent law that the
claims of a patent define the invention to which the…reading the entire patent." Id. at 1321
(internal quotation marks omitted). The patent "specification |
External link to document |
| 2017-06-26 |
315 |
Stipulation of Dismissal |
infringement of
U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), and 8,399,514… alleging infringement of U.S.
Patent No. 7,619,001 (“the ’001 patent”) by submission of Hetero’s ANDA…8,399,514 (“the
’514 patent”) by submission of Hetero’s Abbreviated New Drug Application (“ANDA”) No.
210500…
Product”) prior to the expiration of the ’001 patent, i.e., June 20, 2020.
2. All claims… defenses, and counterclaims regarding the ’001 patent brought in C.A.
No. 19-211 are dismissed without |
External link to document |
| 2017-06-26 |
321 |
Stipulation |
infringement of U.S. Patent Nos.
6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 (“…(“the ’001 patent”)
7,803,840 (“the ’840 patent), 8,759,393 (“the ’393 patent”), and 8,399,514 (“the …the ’514 patent”) by
submission of Sawai’s Abbreviated New Drug Application (“ANDA”) No. 210285: Biogen… of claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent
{01502985;v1 }
Case 1:17-cv-00823-MN Document…that claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent are
invalid for failure to comply with one or |
External link to document |
| 2017-06-26 |
326 |
Stipulation |
-4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the
“Asserted…Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted,
Abbreviated New Drug …WHEREAS claims 5, 7, 14, and 17-20 of the Asserted Patent have not been asserted;
WHEREAS, Zydus…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid or would not be
infringed by the commercial… 26 June 2017
1:17-cv-00823-MN
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
